Winter Clinical Miami, 2024

Bimekizumab efficacy through Year 1 in patients with moderate to severe plaque psoriasis who had not achieved a PASI 90 response by Week 16: A pooled analysis from four phase 3/3b trials

Bimekizumab versus secukinumab continuous maintenance of PASI 90 and PASI 100 responses through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial

Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II

Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials

Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials

Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials